4-o-methyl-12-o-tetradecanoylphorbol 13-acetate has been researched along with sirolimus in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cao, YJ; Du, WX; Huang, YB; Liu, CF; Liu, HH; Shi, LY; Sun, JJ; Wang, F; Yin, XW; Zhang, YL | 1 |
1 other study(ies) available for 4-o-methyl-12-o-tetradecanoylphorbol 13-acetate and sirolimus
Article | Year |
---|---|
Rapamycin inhibits ox-LDL-induced inflammation in human endothelial cells in vitro by inhibiting the mTORC2/PKC/c-Fos pathway.
Topics: Cell Adhesion; Cells, Cultured; Dose-Response Relationship, Drug; E-Selectin; Gene Knockdown Techniques; Genes, fos; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Intercellular Adhesion Molecule-1; Lipoproteins, LDL; Mechanistic Target of Rapamycin Complex 2; Protein Kinase C; Rapamycin-Insensitive Companion of mTOR Protein; Regulatory-Associated Protein of mTOR; RNA, Small Interfering; Signal Transduction; Sirolimus; Staurosporine; Tetradecanoylphorbol Acetate | 2018 |